OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: MindImmune Therapeutics, Inc.

2 Projects | 1 Researchers | $6,849,485 Invested

2026

MindImmune Therapeutics, Inc.

Frank Menniti, PhD

MITI-101, a novel antibody therapeutic to treat Alzheimer's disease and related disorders

  • Funding Amount: $5,014,485
  • Organization Type:
  • Program: Clinical
  • Target: Inflammation
  • Status: Active

2021

MindImmune Therapeutics, Inc.

Frank Menniti, PhD

Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer's disease and other diseases of the central nervous system

  • Funding Amount: $1,835,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Inflammation
  • Status: Active